Stay updated on Safety of Intravitreal APL-2 in Geographic Atrophy Clinical Trial
Sign up to get notified when there's something new on the Safety of Intravitreal APL-2 in Geographic Atrophy Clinical Trial page.

Latest updates to the Safety of Intravitreal APL-2 in Geographic Atrophy Clinical Trial page
- Check7 days agoChange DetectedThe page shows a revision from v3.6.4 to v3.6.5, representing an update to the site's underlying software. This appears to be a maintenance release that does not modify the study data or user-facing content.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedA new revision label v3.6.4 is added, indicating a small deployment update to the page. No substantive study details or user-facing content changes are evident.SummaryDifference0.1%

- Check28 days agoNo Change Detected
- Check43 days agoChange DetectedThe revision indicator on the page has updated from v3.6.2 to v3.6.3, signaling a newer version of the page. This update reflects a version refresh rather than changes to the study information itself.SummaryDifference0.1%

- Check50 days agoChange DetectedThe page footer revision label changed from v3.6.0 to v3.6.2, indicating a newer page version or update to the underlying template.SummaryDifference0.1%

- Check64 days agoChange DetectedRecruitment status on the study page has been updated to 'No longer looking for participants', signaling that enrollment is closed. The page also adds new help/navigation sections such as 'How to Read a Study Record', 'Common Questions', and 'How to Join a Study', and updates the revision label to v3.6.0.SummaryDifference0.5%

- Check71 days agoChange DetectedThe page revision label changed from v3.5.4 to v3.5.5, indicating a new version of the page. This is a metadata update and does not modify the study content.SummaryDifference0.1%

Stay in the know with updates to Safety of Intravitreal APL-2 in Geographic Atrophy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of Intravitreal APL-2 in Geographic Atrophy Clinical Trial page.